Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SUBSTANTIA_NIGRA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Dopaminergic Neuron Loss | decreases_risk | phenotype | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| dopaminergic_neurons | expressed_in | cell_type | 0.72 |
| DOPAMINE_NEURONS | expressed_in | cell_type | 0.72 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| m6A-dependent control of alpha-synuclein transcript fate and | 0.626 | neurodegeneration | m6A RNA Modification and Alpha-Synuclein |
| Cell-state stratification is required to resolve m6A RNA Mod | 0.612 | neurodegeneration | m6A RNA Modification and Alpha-Synuclein |
| Perturbation-first validation should precede therapeutic cla | 0.608 | neurodegeneration | m6A RNA Modification and Alpha-Synuclein |
| AAV-Mediated RGS6 Overexpression in Substantia Nigra Parvoce | 0.424 | neurodegeneration | Does RGS6 upregulation or D2 autorecepto |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.703
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| No experiments found | |||||||
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| No papers found | ||||
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning SUBSTANTIA_NIGRA in their description or question text
No additional research found